Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment 麻豆原创 Research Report 2023

Publication ID:

PB510231876

Publication Date:

October 19, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Progressive familial intrahepatic cholestasis (PFIC) type 2 is a rare genetic disorder that has no curative medication. Key players in the market only provide symptomatic treatment drugs.
The global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment market is projected to reach US$ 340 million in 2029, increasing from US$ 236 million in 2022, with the CAGR of 5.4% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Progressive Familial Intrahepatic Cholestasis Type 2 Treatment market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment market with multiple angles, which provides sufficient supports to readers鈥� strategy and decision making.
By Company
Teva
AbbVie
Glenmark Pharmaceuticals
Par Pharmaceuticals
Mylan
Sanofi
Novartis
Akorn
Albireo Pharma
Mirum Pharmaceuticals
Segment by Type
Ursodeoxycholic Acid
Cholestyramine
Rifampicin
Late Stage Pipeline Drugs
Others
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Progressive Familial Intrahepatic Cholestasis Type 2 Treatment report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. 麻豆原创 Opportunities and Challenges
Chapter 3: Companies鈥� Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies鈥� Outline
Chapter 12: 麻豆原创 Conclusions
Chapter 13: Research Methodology and Data Source

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Ursodeoxycholic Acid
1.2.3 Cholestyramine
1.2.4 Rifampicin
1.2.5 Late Stage Pipeline Drugs
1.2.6 Others
1.3 麻豆原创 by Application
1.3.1 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment 麻豆原创 Perspective (2018-2029)
2.2 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Growth Trends by Region
2.2.1 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment 麻豆原创 Dynamics
2.3.1 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Industry Trends
2.3.2 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment 麻豆原创 Drivers
2.3.3 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment 麻豆原创 Challenges
2.3.4 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Players by Revenue
3.1.1 Global Top Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Players by Revenue (2018-2023)
3.1.2 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue
3.4 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment 麻豆原创 Concentration Ratio
3.4.1 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue in 2022
3.5 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Key Players Head office and Area Served
3.6 Key Players Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Product Solution and Service
3.7 Date of Enter into Progressive Familial Intrahepatic Cholestasis Type 2 Treatment 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Breakdown Data by Type
4.1 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Forecasted 麻豆原创 Size by Type (2024-2029)
5 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Breakdown Data by Application
5.1 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment 麻豆原创 Size (2018-2029)
6.2 North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment 麻豆原创 Size by Country (2018-2023)
6.4 North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment 麻豆原创 Size (2018-2029)
7.2 Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment 麻豆原创 Size by Country (2018-2023)
7.4 Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Progressive Familial Intrahepatic Cholestasis Type 2 Treatment 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Progressive Familial Intrahepatic Cholestasis Type 2 Treatment 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Progressive Familial Intrahepatic Cholestasis Type 2 Treatment 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Progressive Familial Intrahepatic Cholestasis Type 2 Treatment 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment 麻豆原创 Size (2018-2029)
9.2 Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Progressive Familial Intrahepatic Cholestasis Type 2 Treatment 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Progressive Familial Intrahepatic Cholestasis Type 2 Treatment 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Progressive Familial Intrahepatic Cholestasis Type 2 Treatment 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Progressive Familial Intrahepatic Cholestasis Type 2 Treatment 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Teva
11.1.1 Teva Company Detail
11.1.2 Teva Business Overview
11.1.3 Teva Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Introduction
11.1.4 Teva Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2023)
11.1.5 Teva Recent Development
11.2 AbbVie
11.2.1 AbbVie Company Detail
11.2.2 AbbVie Business Overview
11.2.3 AbbVie Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Introduction
11.2.4 AbbVie Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2023)
11.2.5 AbbVie Recent Development
11.3 Glenmark Pharmaceuticals
11.3.1 Glenmark Pharmaceuticals Company Detail
11.3.2 Glenmark Pharmaceuticals Business Overview
11.3.3 Glenmark Pharmaceuticals Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Introduction
11.3.4 Glenmark Pharmaceuticals Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2023)
11.3.5 Glenmark Pharmaceuticals Recent Development
11.4 Par Pharmaceuticals
11.4.1 Par Pharmaceuticals Company Detail
11.4.2 Par Pharmaceuticals Business Overview
11.4.3 Par Pharmaceuticals Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Introduction
11.4.4 Par Pharmaceuticals Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2023)
11.4.5 Par Pharmaceuticals Recent Development
11.5 Mylan
11.5.1 Mylan Company Detail
11.5.2 Mylan Business Overview
11.5.3 Mylan Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Introduction
11.5.4 Mylan Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2023)
11.5.5 Mylan Recent Development
11.6 Sanofi
11.6.1 Sanofi Company Detail
11.6.2 Sanofi Business Overview
11.6.3 Sanofi Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Introduction
11.6.4 Sanofi Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2023)
11.6.5 Sanofi Recent Development
11.7 Novartis
11.7.1 Novartis Company Detail
11.7.2 Novartis Business Overview
11.7.3 Novartis Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Introduction
11.7.4 Novartis Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2023)
11.7.5 Novartis Recent Development
11.8 Akorn
11.8.1 Akorn Company Detail
11.8.2 Akorn Business Overview
11.8.3 Akorn Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Introduction
11.8.4 Akorn Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2023)
11.8.5 Akorn Recent Development
11.9 Albireo Pharma
11.9.1 Albireo Pharma Company Detail
11.9.2 Albireo Pharma Business Overview
11.9.3 Albireo Pharma Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Introduction
11.9.4 Albireo Pharma Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2023)
11.9.5 Albireo Pharma Recent Development
11.10 Mirum Pharmaceuticals
11.10.1 Mirum Pharmaceuticals Company Detail
11.10.2 Mirum Pharmaceuticals Business Overview
11.10.3 Mirum Pharmaceuticals Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Introduction
11.10.4 Mirum Pharmaceuticals Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2023)
11.10.5 Mirum Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Teva
AbbVie
Glenmark Pharmaceuticals
Par Pharmaceuticals
Mylan
Sanofi
Novartis
Akorn
Albireo Pharma
Mirum Pharmaceuticals

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.